PF-04965842 + probenecid

**PF-04965842 + probenecid** is a combination of two small molecule drugs. PF-04965842, also known as abrocitinib, is an oral Janus kinase 1 (JAK1) inhibitor developed for the treatment of inflammatory diseases, particularly moderate to severe atopic dermatitis. Its mechanism involves selectively inhibiting JAK1, thereby modulating cytokine signalling implicated in inflammation, including interleukin-4, interleukin-13, interleukin-31, and interferon gamma[1][3][5]. Probenecid is an oral uricosuric agent that inhibits renal tubular reabsorption of uric acid; it is often used to increase blood levels of certain drugs by delaying their excretion, but there is currently no published evidence that PF-04965842 is clinically combined or co-developed with probenecid for any approved or investigational purpose. The specific combination presented (PF-04965842 + probenecid) does not represent an approved or recognized pharmaceutical product based on the available evidence.

Brand names

abrocitinib

Other names

PF-04965842 + probenecid